Agreement - November 1, 2023
AstraZeneca enters agreement with Cellectis
AstraZeneca has announced a collaboration and investment agreement with the French clinical-stage biotechnology company Cellectis to accelerate the development of next generation therapeutics in areas of high unmet need, including oncology, immunology and rare diseases. Under the terms of the collaboration agreement, AstraZeneca will leverage the Cellectis gene editing technologies and manufacturing capabilities, to design […]
Agreement - October 23, 2023
Nanoform grant AI License to AstraZeneca
Nanoform Finland has granted AstraZeneca a global online STARMAP license. STARMAP is a digital AI version of the CESS technology that enables in-silico experiments to determine which molecules should be nanoformed. The license will enable AstraZeneca to screen molecules from drug discovery through to lifecycle management, describes Nanoform in a press release. Access to compound […]
Agreement - October 16, 2023
Spark Therapeutics terminates agreement with CombiGene
CombiGene will regain the global rights for the epilepsy project CG01 from Spark Therapeutics by January 12, 2024. The collaboration agreement between CombiGene and Spark Therapeutics, which was signed in October 2021, shall be terminated because of a strategic decision by Spark Therapeutics to deprioritize the further development of CG01 in epilepsy as part of […]
Agreement - August 16, 2023
Sprint Bioscience licenses program to Day One Biopharmaceuticals
Sprint Bioscience has licensed the global rights to its cancer program VADA (VRK1) to Day One Biopharmaceuticals Inc. “This agreement is yet another confirmation that the work we do within the company is of the highest international class. The VADA (VRK1) program has generated great interest in the industry globally and we have chosen Day […]
Agreement - August 9, 2023
Evaxion announces financing commitments totaling up to 20 MUSD
Evaxion Biotech has entered into a binding agreement for a financing of up to 20 million USD with Negma Group Investment. “We are pleased to be able to establish a flexible financing vehicle with Negma Group. The ability to attract such an experienced investor is a tribute to Evaxion’s AI technology and pipeline progress,” says […]
Acquisition - August 4, 2023
Alexion, AstraZeneca Rare Disease, enters agreement with Pfizer
Alexion, AstraZeneca Rare Disease, has entered a definitive purchase and licence agreement for a portfolio of preclinical gene therapy programmes and enabling technologies from Pfizer. The agreement furthers Alexion and AstraZeneca’s commitment to advancing next-generation genomic medicines with the addition of complementary pipeline assets and innovative technologies, it states. Alexion will purchase and licence the […]
